5tfa: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
'''Unreleased structure''' | '''Unreleased structure''' | ||
The entry 5tfa is ON HOLD until | The entry 5tfa is ON HOLD until Apr 30 2019 | ||
Authors: Wang, C., Aleksandrov, A.A., Yang, Z., Forouhar, F., Proctor, E., Kota, P., An, J., Kaplan, A., Khazanov, N., Boel, G., Stockwell, B.R., Senderowitz, H., Dokholyan, N.V., Riordan, J.R., Brouillette, C.G., Hunt, J.F. | Authors: Wang, C., Aleksandrov, A.A., Yang, Z., Forouhar, F., Proctor, E., Kota, P., An, J., Kaplan, A., Khazanov, N., Boel, G., Stockwell, B.R., Senderowitz, H., Dokholyan, N.V., Riordan, J.R., Brouillette, C.G., Hunt, J.F. | ||
Revision as of 08:05, 28 March 2018
Unreleased structure
The entry 5tfa is ON HOLD until Apr 30 2019
Authors: Wang, C., Aleksandrov, A.A., Yang, Z., Forouhar, F., Proctor, E., Kota, P., An, J., Kaplan, A., Khazanov, N., Boel, G., Stockwell, B.R., Senderowitz, H., Dokholyan, N.V., Riordan, J.R., Brouillette, C.G., Hunt, J.F.
Description: Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR) with dUTP